Research output: Contribution to journal › Review article › peer-review
Adenovirus type 6: Subtle structural distinctions from adenovirus type 5 result in essential differences in properties and perspectives for gene therapy. / Romanenko, Margarita; Osipov, Ivan; Netesov, Sergey V. et al.
In: Pharmaceutics, Vol. 13, No. 10, 1641, 10.2021.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Adenovirus type 6: Subtle structural distinctions from adenovirus type 5 result in essential differences in properties and perspectives for gene therapy
AU - Romanenko, Margarita
AU - Osipov, Ivan
AU - Netesov, Sergey V.
AU - Davydova, Julia
N1 - Funding Information: Funding: This study was supported by NIH NCI R01CA174861 (JD); NIH NCI R01CA228760 (JD); and the FSUS-2020-0035 grant from Russian Ministry of Science and Higher Education (SN). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/10
Y1 - 2021/10
N2 - Adenovirus vectors are the most frequently used agents for gene therapy, including on-colytic therapy and vaccine development. It’s hard to overestimate the value of adenoviruses during the COVID-19 pandemic as to date four out of four approved viral vector-based SARS-CoV-2 vaccines are developed on adenovirus platform. The vast majority of adenoviral vectors are based on the most studied human adenovirus type 5 (HAdV-C5), however, its immunogenicity often ham-pers the clinical translation of HAdV-C5 vectors. The search of less seroprevalent adenovirus types led to another species C adenovirus, Adenovirus type 6 (HAdV-C6). HAdV-C6 possesses high on-colytic efficacy against multiple cancer types and remarkable ability to induce the immune response towards carrying antigens. Being genetically very close to HAdV-C5, HAdV-C6 differs from HAdV-C5 in structure of the most abundant capsid protein, hexon. This leads to the ability of HAdV-C6 to evade the uptake by Kupffer cells as well as to distinct opsonization by immunoglobulins and other blood proteins, influencing the overall biodistribution of HAdV-C6 after systemic administration. This review describes the structural features of HAdV-C6, its interaction with liver cells and blood factors, summarizes the previous experiences using HAdV-C6, and provides the rationale behind the use of HAdV-C6 for vaccine and anticancer drugs developments.
AB - Adenovirus vectors are the most frequently used agents for gene therapy, including on-colytic therapy and vaccine development. It’s hard to overestimate the value of adenoviruses during the COVID-19 pandemic as to date four out of four approved viral vector-based SARS-CoV-2 vaccines are developed on adenovirus platform. The vast majority of adenoviral vectors are based on the most studied human adenovirus type 5 (HAdV-C5), however, its immunogenicity often ham-pers the clinical translation of HAdV-C5 vectors. The search of less seroprevalent adenovirus types led to another species C adenovirus, Adenovirus type 6 (HAdV-C6). HAdV-C6 possesses high on-colytic efficacy against multiple cancer types and remarkable ability to induce the immune response towards carrying antigens. Being genetically very close to HAdV-C5, HAdV-C6 differs from HAdV-C5 in structure of the most abundant capsid protein, hexon. This leads to the ability of HAdV-C6 to evade the uptake by Kupffer cells as well as to distinct opsonization by immunoglobulins and other blood proteins, influencing the overall biodistribution of HAdV-C6 after systemic administration. This review describes the structural features of HAdV-C6, its interaction with liver cells and blood factors, summarizes the previous experiences using HAdV-C6, and provides the rationale behind the use of HAdV-C6 for vaccine and anticancer drugs developments.
KW - Ad5
KW - Ad6
KW - Adenovirus
KW - Immunother-apy
KW - Kupffer cells
KW - Liver tropism
KW - Oncolytic viruses
KW - Serotype 6
KW - Vaccine
KW - Virotherapy
UR - http://www.scopus.com/inward/record.url?scp=85117318426&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/98b6866f-cd53-3143-879f-ff1a118499e7/
U2 - 10.3390/pharmaceutics13101641
DO - 10.3390/pharmaceutics13101641
M3 - Review article
C2 - 34683934
AN - SCOPUS:85117318426
VL - 13
JO - Pharmaceutics
JF - Pharmaceutics
SN - 1999-4923
IS - 10
M1 - 1641
ER -
ID: 34453934